The 5 Most Interesting Analyst Questions From SS&C’s Q2 Earnings Call

SS&C’s second quarter results drew a strongly positive market reaction, as the company outperformed Wall Street’s revenue and non-GAAP profit expectations. Management attributed this to a combination of large technology license renewals, continued momentum in multiyear client contracts, and successful integration of recent acquisitions. CEO Bill Stone emphasized that organic revenue growth was boosted by the timing of major contract renewals, stating, “We did have a couple of big renewals in Q2, and that’s why organic revenue was up a couple of hundred extra basis points.” The quarter also benefited from robust demand in fund administration, with assets under administration up notably over the past two years.

Is now the time to buy SSNC? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From SS&C’s Q2 Earnings Call

• Daniel Perlin (RBC Capital Markets) asked for more detail on the drivers behind organic growth, particularly the impact of large license renewals. CEO Bill Stone explained that the timing of contract renewals can cause spikes in revenue and highlighted their increasing frequency as the business scales.
• Jeffrey Schmitt (William Blair) inquired about the impact of AI adoption on outsourcing demand. President Rahul Kanwar responded that customers increasingly turn to SS&C for scalable AI-driven automation, as building comparable solutions internally is more challenging.
• Kevin McVeigh (UBS) asked about the scalability and financial impact of the Medicare GLP-1 Bridge program on DomaniRx. Bill Stone noted the program’s early popularity but cautioned that its long-term contribution depends on government decisions regarding program continuation.
• Isabella Camaj (JPMorgan) sought clarity on the implications of renewal timing for organic growth in the second half of the year. Bill Stone said there are upcoming renewals that could provide upside, but the company will not speculate on the timing.
• Peter Heckmann (D.A. Davidson) probed the drivers behind the Intralinks business rebound. President Kanwar cited positive pipeline conversion and new client wins, especially in virtual data rooms and alternative asset communication.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will focus on (1) the pace of adoption for Agentic AI and automation platforms across enterprise clients, (2) the scalability and renewal of healthcare initiatives such as the Medicare GLP-1 Bridge on DomaniRx, and (3) continued execution in integrating and expanding the Calastone and Curo acquisitions. Sustained growth in fund administration and further large contract renewals will also be key indicators to watch.

SS&C currently trades at $78.34, up from $66.95 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.